Dataset Information

The Societal Value of Broader Access to Antiobesity Medications.

ABSTRACT:

Objective

Obesity and its complications place an enormous burden on society. Yet antiobesity medications (AOM) are prescribed to only 2% of the eligible population, even though few individuals can sustain weight loss using other strategies alone. This study estimated the societal value of greater access to AOM.

Methods

By using a well-established simulation model (The Health Economics Medical Innovation Simulation), the societal value of AOM for the cohort of Americans aged ??25 years in 2019 was quantified. Four scenarios with differential uptake among the eligible population (15% and 30%) were modeled, with efficacy from current and next-generation AOM. Societal value was measured as monetized quality of life, productivity gains, and savings in medical spending, subtracting the costs of AOM.

Results

For the 217 million Americans aged ??25 years, AOM generated $1.2 trillion in lifetime societal value under a conservative scenario (15% annual uptake using currently available AOM). The introduction of next-generation AOM increased societal value to $1.9 to $2.5 trillion, depending on uptake. Finally, societal value was higher for younger individuals and Black and Hispanic individuals compared with White individuals.

Conclusions

This study suggests that AOM provide substantial gains to patients and society. Policies promoting broader clinical access to and use of AOM warrant consideration to reach national goals to reduce obesity.

SUBMITTER: Kabiri M

PROVIDER: S-EPMC7003734 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

The Societal Value of Broader Access to Antiobesity Medications.

Kabiri Mina M Sexton Ward Alison A Ramasamy Abhilasha A van Eijndhoven Emma E Ganguly Rahul R Smolarz B Gabriel BG Zvenyach Tracy T Goldman Dana P DP Baumgardner James R JR

Obesity (Silver Spring, Md.) 20191223 2

<h4>Objective</h4>Obesity and its complications place an enormous burden on society. Yet antiobesity medications (AOM) are prescribed to only 2% of the eligible population, even though few individuals can sustain weight loss using other strategies alone. This study estimated the societal value of greater access to AOM.<h4>Methods</h4>By using a well-established simulation model (The Health Economics Medical Innovation Simulation), the societal value of AOM for the cohort of Americans aged ≥ 25 y ...[more]

PMID: 31869002

Similar Datasets

Project description:Many health technology assessment (HTA) agencies limit their assessments of vaccines to the health benefits for the vaccinated individual, the costs associated with vaccine administration and the disease avoided. However, because the value of vaccines tends to accrue to a large extent beyond the vaccinated individual, they are systematically undervalued in many current HTA processes. This is also the case in the UK, where the Joint Committee on Vaccination and Immunisation (JCVI) is in charge of assessing preventative vaccines, while therapeutic vaccines fall in the realm of the National Institute for Clinical Excellence (NICE). To contribute to a forward-looking perspective, we designed a framework to capture the broader value of vaccination. We reviewed the current state of the global vaccines pipeline and selected seven preventative and three therapeutic vaccines that are likely to enter the UK market within five years. We assessed on which value elements the selected vaccines would potentially generate value, and compared those against the novel broader value framework. A review of the current value elements considered by the JCVI and NICE allowed identifying the critical gaps between potential value generation and value recognition. To our knowledge, this is the first time that the broader value of vaccination has been pro-actively assessed for pipeline vaccinations. Our findings show that the existing narrow evaluation frameworks are likely to systematically undervalue the value of potential future vaccines coming to the UK market. This is particularly relevant, where their impact on AMR and other health interventions, and on the productivity of the workforce is of concern. Recommendations to overcome this include an explicit and more consistent inclusion of, and data collection on, the impact of vaccines on AMR and other health interventions by JCVI and NICE; the consideration of a societal perspective and the fiscal impact of vaccines to societies.

Project description:BackgroundAlthough rotator cuff disease is a common musculoskeletal problem in the United States, the impact of this condition on earnings, missed workdays, and disability payments is largely unknown. This study examines the value of surgical treatment for full-thickness rotator cuff tears from a societal perspective.MethodsA Markov decision model was constructed to estimate lifetime direct and indirect costs associated with surgical and continued nonoperative treatment for symptomatic full-thickness rotator cuff tears. All patients were assumed to have been unresponsive to one six-week trial of nonoperative treatment prior to entering the model. Model assumptions were obtained from the literature and data analysis. We obtained estimates of indirect costs using national survey data and patient-reported outcomes. Four indirect costs were modeled: probability of employment, household income, missed workdays, and disability payments. Direct cost estimates were based on average Medicare reimbursements with adjustments to an all-payer population. Effectiveness was expressed in quality-adjusted life years (QALYs).ResultsThe age-weighted mean total societal savings from rotator cuff repair compared with nonoperative treatment was $13,771 over a patient's lifetime. Savings ranged from $77,662 for patients who are thirty to thirty-nine years old to a net cost to society of $11,997 for those who are seventy to seventy-nine years old. In addition, surgical treatment results in an average improvement of 0.62 QALY. Societal savings were highly sensitive to age, with savings being positive at the age of sixty-one years and younger. The estimated lifetime societal savings of the approximately 250,000 rotator cuff repairs performed in the U.S. each year was $3.44 billion.ConclusionsRotator cuff repair for full-thickness tears produces net societal cost savings for patients under the age of sixty-one years and greater QALYs for all patients. Rotator cuff repair is cost-effective for all populations. The results of this study should not be interpreted as suggesting that all rotator cuff tears require surgery. Rather, the results show that rotator cuff repair has an important role in minimizing the societal burden of rotator cuff disease.

Project description:IntroductionLittle is known about the accuracy of societal publications (e.g. press releases, internet postings or professional journals) that are based on scientific work. This study investigates a) inconsistencies between scientific peer-reviewed health services research (HSR) publications and non-scientific societal publications and b) replication of reporting inadequacies from these scientific publications to corresponding societal publications.MethodsA sample of HSR publications was drawn from 116 publications authored in 2016 by thirteen Dutch HSR institutions. Societal publications corresponding to scientific publications were identified through a systematic internet search. We conducted a qualitative, directed content analysis on societal publications derived from the scientific publications to assess both reporting inadequacies and determine inconsistencies. Descriptive frequencies were calculated for all variables. Odds ratios were used to investigate whether inconsistencies in societal publications were less likely when the first scientific author was involved.ResultsWe identified 43 scientific and 156 societal publications. 94 societal publications (60.3%), (associated with 32 scientific publications (74.4%)) contained messages that were inconsistent with the scientific work. We found reporting inadequacies in 22 scientific publications (51.2%). In 45 societal publications (28.9%), we found replications of these reporting inadequacies. The likelihood of inconsistencies between scientific and societal publications did not differ when the latter explicitly involved the first scientific author, (OR = 1.44, CI: 0.76-2.74); were published on the institute's or funder's website, (OR = 1.32, CI: 0.57-3.06); published with no involvement of a scientific author, (OR = 0.52, CI: 0.25-1.07).ConclusionTo improve societal publications, one should examine both the consistency with scientific research publications and ways to prevent replication of scientific reporting inadequacies. HSR institutions, funders, and scientific and societal publication platforms should invest in a supportive publication culture to further incentivise the responsible and skilled involvement of researchers in writing both scientific and societal publications.

Project description:BackgroundThe COVID-19 pandemic shows that the impact of effective vaccines can extend well beyond vaccinated individuals and healthcare systems. Yet, these broader value elements are not typically considered in Health Technology Assessment (HTA) which may underestimate vaccines' broader value.ObjectivesThis study aimed to (1) describe the gap between broader value elements identified in value frameworks for vaccines and those recognised in HTA of vaccines in nine developed markets, and (2) develop expert-informed, consensus-based recommendations on how hurdles for broader value recognition could be overcome.MethodsWe used a four-step modified Delphi method consisting of literature research (phase I, pearl-growing approach using PubMed Web of Science and Google covering the years 2000-2019), two consecutive phases of expert elicitation (phase II and III, including two email surveys and one virtual round table with 10 experts from 9 countries) and synthesis of recommendations (phase IV).ResultsResults show that about half of the broader value elements relevant to vaccines are not (consistently) considered in HTA processes of multiple higher-income countries. Experts identified five priority areas for broader value recognition, including considering (1) more comprehensive cost offsets within the health care system, (2) carer quality of life, (3) transmission value, (4) prevention of antimicrobial resistance and (5) macroeconomic effects.ConclusionTo achieve a broader recognition of the value of vaccines, a three-pronged approach was recommended, focusing on (1) Evidence: proactively steering generation of high-quality evidence to quantify the broader value of vaccines to society; (2) Ability: leveraging and further developing existing methodological and analytic expertise to appropriately recognise the broad value of vaccines within HTA processes; (3) Willingness: Stimulating stakeholder engagement to change the status quo and move towards more transparent and comprehensive value assessment processes for vaccines globally.

Dataset Information

The Societal Value of Broader Access to Antiobesity Medications.

Objective

Methods

Results

Conclusions

Publications

The Societal Value of Broader Access to Antiobesity Medications.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets